Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 3 | 0 | 0 | 1 | 0 |
Analyst Firms Making Recommendations1
- Barclays
- EF Hutton
- Guggenheim
- Wells Fargo
- Mizuho
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Adaptimmune Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 08/10/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 89.65% | Barclays | Peter Lawson | $2 → $1 | Maintains | Underweight | Get Alert |
| 08/10/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1796.45% | EF Hutton | Tony Butler | → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1796.45% | EF Hutton | Tony Butler | → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1796.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 05/26/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1796.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1796.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1796.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1796.45% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1796.45% | EF Hutton | Tony Butler | → $10 | Initiates | → Buy | Get Alert |
| 01/03/2023 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 848.23% | Guggenheim | Michael Schmidt | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 11/14/2022 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 468.94% | Wells Fargo | Yanan Zhu | $1.5 → $3 | Maintains | Equal-Weight | Get Alert |
| 11/09/2022 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1606.81% | Mizuho | Mara Goldstein | → $9 | Upgrade | Neutral → Buy | Get Alert |
| 10/04/2022 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 184.47% | Wells Fargo | Nick Abbott | $7 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 05/09/2022 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 468.94% | SVB Leerink | Jonathan Chang | $2 → $3 | Maintains | Market Perform | Get Alert |
| 03/15/2022 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 468.94% | SVB Leerink | Jonathan Chang | $7 → $3 | Maintains | Market Perform | Get Alert |
| 09/22/2021 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1227.52% | Wells Fargo | — | — | Maintains | Equal-Weight | Get Alert |
| 09/13/2021 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1227.52% | SVB Leerink | Jonathan Chang | — | Maintains | Market Perform | Get Alert |
| 09/07/2021 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 1037.87% | SVB Leerink | Jonathan Chang | — | Maintains | Market Perform | Get Alert |
| 08/10/2021 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.53 | 848.23% | SVB Leerink | Jonathan Chang | — | Maintains | Market Perform | Get Alert |
What is the target price for Adaptimmune Therapeutics (ADAP)?
The latest price target for Adaptimmune Therapeutics (NASDAQ: ADAP) was reported by Barclays on August 10, 2023. The analyst firm set a price target for $1.00 expecting ADAP to rise to within 12 months (a possible 89.65% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adaptimmune Therapeutics (ADAP)?
The latest analyst rating for Adaptimmune Therapeutics (NASDAQ: ADAP) was provided by Barclays, and Adaptimmune Therapeutics maintained their underweight rating.
When is the next analyst rating going to be posted or updated for Adaptimmune Therapeutics (ADAP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptimmune Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptimmune Therapeutics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating Adaptimmune Therapeutics (ADAP) correct?
While ratings are subjective and will change, the latest Adaptimmune Therapeutics (ADAP) rating was a maintained with a price target of $2.00 to $1.00. The current price Adaptimmune Therapeutics (ADAP) is trading at is $0.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.